Results 11 to 20 of about 3,353 (184)
Antibiotics, 2023 Background: Pseudomonas aeruginosa shows resistance to several antibiotics and often develops such resistance during patient treatment. Objective: Develop an in vitro model, using clinical isolates of P. aeruginosa, to compare the ability of the imipenem
Maria Paz Ventero +8 more
doaj +6 more sources
In vitro efficacy of relebactam versus avibactam against Mycobacterium abscessus complex [PDF]
The Cell Surface, 2021 Infections resulting from Mycobacterium abscessus are increasing in prevalence worldwide, with the greatest risk posed to patients with underlying respiratory conditions.
James Harrison +3 more
doaj +5 more sources
AmpC β-lactamase induction by avibactam and relebactam [PDF]
Journal of Antimicrobial Chemotherapy, 2017 Diazabicyclooctanes, e.g. avibactam and relebactam, are a new class of β-lactamase inhibitors. Their spectrum includes AmpC enzymes, but it is important to understand whether they also induce these enzymes.Levels of ampC mRNA were measured by RT-PCR during 4 h of exposure of Enterobacter cloacae, Citrobacter freundii and Pseudomonas aeruginosa (n = 5 ...
Livermore, David M +5 more
openaire +6 more sources
Imipenem-Relebactam Susceptibility in Enterobacterales Isolates Recovered from ICU Patients from Spain and Portugal (SUPERIOR and STEP Studies) [PDF]
Microbiology Spectrum, 2022 Imipenem-relebactam is a novel β-lactam-β-lactamase inhibitor combination. We evaluated the in vitro activity of imipenem-relebactam and comparators against Enterobacterales clinical isolates recovered in 8 Spanish and 11 Portuguese intensive care units (
Marta Hernández-García +23 more
doaj +3 more sources
PLoS ONE, 2020 Imipenem/cilastatin/relebactam is a β-lactam/β-lactamase inhibitor that has been recently FDA approved for complicated intra-abdominal and urinary tract infections under the brand name Recarbrio®.
Islam M Ghazi +5 more
doaj +5 more sources
Inactivation of the Pseudomonas-Derived Cephalosporinase-3 (PDC-3) by Relebactam [PDF]
Antimicrobial Agents and Chemotherapy, 2018 ABSTRACT Pseudomonas aeruginosa is a prevalent and life-threatening Gram-negative pathogen. Pseudomonas -derived cephlosporinase (PDC) is the major inducible cephalosporinase in P. aeruginosa .
Melissa D, Barnes +6 more
openaire +3 more sources
Antibiotics, 2023 Background: Despite the availability of new options (ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam and cefiderocol), it is still very difficult to treat infections caused by metallo-β-lactamase (MBLs)-producers resistant to aztreonam.
Cécile Emeraud +2 more
doaj +2 more sources
Effect of Amoxicillin in combination with Imipenem-Relebactam against Mycobacterium abscessus [PDF]
Scientific Reports, 2020 AbstractInfections caused by Mycobacterium abscessus are increasing in prevalence in cystic fibrosis patients. This opportunistic pathogen′s intrinsic resistance to most antibiotics has perpetuated an urgent demand for new, more effective therapeutic interventions. Here we report a prospective advance in the treatment of M.
Rose C. Lopeman +5 more
openaire +5 more sources
New evidence in severe pneumonia: imipenem/ cilastatin/relebactam
Revista Española de Quimioterapia, 2022 Imipenem combined with beta-lactamase inhibitor relebactam (IMI/REL) has an extensive bactericidal activity against Gram-negative pathogens producing class A or class C beta-lactamases, not active against class B and class D. The phase 3 clinical trial (RESTORE-IMI-2), double-blind, randomized, evaluated IMI/REL vs.
Girón, R M +3 more
openaire +5 more sources
Antimicrobial Agents and ChemotherapyImipenem/relebactam is a promising therapy for complicated intra-abdominal infections caused by carbapenem-resistant Enterobacterales species. However, data on tissue-site pharmacokinetics are limited.
Huan Tong +7 more
doaj +2 more sources